Medical Necessity and Standard of Care Assessment for Primary Immunodeficiency Diseases

Diagnostic Criteria and Medical Necessity

The American Thoracic Society recommends that immunoglobulin replacement therapy be justified by documented primary immunodeficiency diseases (PIDs) with confirmed hypogammaglobulinemia and recurrent bacterial infections 1
The American Academy of Allergy, Asthma, and Immunology suggests that diagnostic criteria for medical necessity include confirmed hypogammaglobulinemia, documented antibody deficiency, and clinical evidence of recurrent infections 2
Patients with documented PID and hypogammaglobulinemia (IgG <500 mg/dL) may be considered for immunoglobulin replacement therapy, according to the American College of Chest Physicians 1
The American Academy of Allergy, Asthma, and Immunology recommends that patients have functional antibody deficiency confirmed by vaccine response testing, a history of recurrent documented bacterial infections, and an appropriate dose for their weight (6 grams total weekly, NOT per kilogram) 2

The American Academy of Allergy, Asthma, and Immunology states that immunoglobulin replacement is standard of care for PIDs based on decades of clinical use and consensus guidelines 1
The American College of Allergy, Asthma, and Immunology suggests that Cuvitru 6 grams weekly is standard of care, NOT experimental, when used for FDA-approved indication (primary immunodeficiency) and patient meets diagnostic criteria for PID with hypogammaglobulinemia 2
The American Society of Hematology recommends that immunoglobulin therapy be used for conditions with established evidence, such as primary immunodeficiency diseases, and not for vague symptoms without objective immunodeficiency 3, 4

The American College of Chest Physicians recommends that laboratory confirmation of hypogammaglobulinemia, vaccine response testing results, and detailed infection history be included in documentation to support medical necessity 1
The American Academy of Allergy, Asthma, and Immunology suggests that patient weight, exclusion of secondary causes of immunodeficiency, and previous treatment attempts and responses be documented to verify dose appropriateness and medical necessity 2